Full-Time

Associate Director

Medical Grants and Sponsorship

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$169.4k - $266.2k/yr

Cambridge, MA, USA

In Person

On-site role in Kendall Square, Cambridge, Massachusetts.

Bachelor's, Master's, MBA, PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Takeda

See people who can refer or advise you

Requirements
  • Degree in life sciences, pharmacy, medicine, medical education, public health, healthcare management, business or related discipline required; advanced degree such as MD, PharmD, PhD, MPH, MSc, MBA or equivalent preferred
  • 8+ years of experience in Medical Affairs, Medical Education, Grants Management, Sponsorships, Medical Governance, Compliance, or related functions within biopharma, biotech or healthcare; 10+ years preferred for broader global scope
  • Strong understanding of independent medical education, medical grants, sponsorships, donations, HCO/HCP interactions, funding independence, provider relationships, letters of agreement, transparency/disclosure expectations and global/local execution realities
  • Experience developing or implementing governance frameworks, SOPs, control models, committee processes, decision criteria, audit-readiness activities, dashboards, reporting routines or cross-functional operating models
  • Experience with grant-management systems, data quality, repository management, documentation standards, budget tracking, reconciliation, metrics and close-out processes preferred
  • Experience working across multiple countries, regions or markets with varied maturity levels, regulatory environments and industry-code expectations preferred
  • Ability to translate enterprise governance expectations into simple, usable tools and guidance that support consistent execution without adding unnecessary complexity
  • Strong governance, risk-based thinking and systems-thinking capability, with the ability to convert complex funding and compliance requirements into practical enterprise standards and decision tools
  • Strong portfolio judgment, including the ability to identify patterns, trade-offs, budget implications and systemic execution risks across multiple Therapeutic Areas, geographies and funding categories
  • Excellent cross-functional leadership, communication, influence and stakeholder-management skills across cultures, functions and seniority levels
  • Executive communication skills, with the ability to frame status, implications, options, risks and recommendations in a concise, leadership-ready manner
  • Ability to balance compliance rigor with operational practicality, avoiding unnecessary bureaucracy while maintaining strong patient, scientific, quality and company safeguards
  • High attention to detail, clarity and documentation quality, with sound judgment in confidential, sensitive or reputationally important situations
  • Ability to support transformation and change management by helping teams adopt new standards, tools, systems, processes and ways of working
  • Commitment to Takeda's values and to advancing a patient-first, science-led and ethically grounded Medical culture globally
Responsibilities
  • Establish, maintain and evolve enterprise governance standards for medical grants, medical education grants and sponsorships to ensure consistent quality, transparency, accountability, appropriate oversight and compliance across global markets
  • Translate enterprise Medical and Therapeutic Area priorities into practical funding frameworks, including defined areas of scientific and educational interest, unmet need statements, prioritization criteria and funding guardrails
  • Shape and maintain the global areas of scientific and educational interest for grants and sponsorships in partnership with Global Therapeutic Areas and Medical leadership, ensuring that external funding priorities are clearly linked to unmet need, Medical strategy, disease-area priorities, patient-centric outcomes and independence requirements
  • Drive portfolio-level prioritization across Therapeutic Areas, geographies, proactive funding opportunities, calls for grants, strategic initiatives, and reactive/unsolicited requests, balancing Medical priorities, unmet need, patient/public health impact, budget availability, fairness of review, and independence requirements
  • Define and continuously refine decision criteria, review pathways, governance standards and decision rights so that funding decisions are anchored in unmet need, patient-centric outcomes, scientific merit, transparency, and compliance
  • Chair and/or facilitate Grant Review Committee meetings, including agenda setting, pre-read review, request summaries, structured discussion, conflict-of-interest considerations, voting integrity, decision documentation and follow-up actions
  • Ensure appropriate cross-functional representation and input from Medical, Global Therapeutic Areas, Ethics & Compliance, Legal, Finance, regional and local Medical teams where relevant to the nature of the request
  • Oversee lifecycle governance for external funding requests from intake and eligibility review through committee decision, agreement handoff, milestone and payment visibility, reconciliation tracking, outcomes reporting, close-out and archiving
  • Assess grant and sponsorship requests against consistent criteria, including requester eligibility, needs assessment, scientific or educational objectives, provider qualifications, program design, audience, budget, deliverables, outcomes plan, disclosure needs and potential risk indicators
  • Maintain governance visibility through grant-management systems, repositories, documentation standards, status tracking, budget commitments, decision rationale, dashboards, metrics and leadership-ready summaries
  • Partner with Finance to support budget planning, forecasting, tracking, reconciliation and visibility across Therapeutic Areas, regions and funded activity types, while maintaining clear separation between funding strategy and inappropriate commercial influence
  • Partner with Legal and Ethics & Compliance to ensure appropriate agreements, templates, policy interpretation, transparency/disclosure requirements, issue escalation and remediation steps are embedded into the process
  • Provide clear process guidance to grant requestors and internal stakeholders on request requirements, submission timelines, documentation expectations, decision outcomes and close-out obligations, while preserving the independence of funded activities
  • Develop and maintain practical operating materials, including intake questions, checklists, templates, committee charters, decision logs, SOP/standard inputs, training materials, knowledge-management resources and user guidance for grant-management systems
  • Support audit readiness, governance reviews, quality checks, risk assessments, gap analyses, remediation planning, issue escalation and CAPA-related activities for grants and sponsorship governance in collaboration with the broader Medical Governance Office
  • Drive continuous improvement by introducing reusable tools, digital intake or documentation workflows, dashboards, process simplification and benchmarking insights that improve transparency, efficiency and consistency without adding unnecessary bureaucracy
  • Provide strategic guidance to the Head, Medical Governance Office and senior Medical leadership on funding strategy, portfolio trade-offs, recurring gaps, emerging external education needs, sponsorship governance, committee effectiveness and operating model implications
  • Represent the Medical Governance Office in relevant grants, sponsorships, medical education, external funding, data/system, audit-readiness and cross-functional governance discussions, ensuring enterprise expectations are clearly understood and practically embedded
  • Capture and share learnings, best practices, outcome insights and common market needs to strengthen the enterprise funding governance foundation and inform future areas of scientific and educational interest
Desired Qualifications
  • Advanced degree such as MD, PharmD, PhD, MPH, MSc, MBA or equivalent preferred
  • 10+ years of experience in Medical Affairs, Medical Education, Grants Management, Sponsorships, Medical Governance, Compliance, or related functions within biopharma, biotech or healthcare;
  • Experience with grant-management systems, data quality, repository management, documentation standards, budget tracking, reconciliation, metrics and close-out processes preferred
  • Experience working across multiple countries, regions or markets with varied maturity levels, regulatory environments and industry-code expectations preferred

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.